Evidence map›Paper›PMID 29666562›Full record

ArticleContrast media & molecular imaging2018

Preclinical

T Balber, J Singer, N Berroterán-Infante, M Dumanic, L Fetty, J Fazekas-Singer, C Vraka, L Nics, M Bergmann, K Pallitsch and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Towards Dual-Tracer SPECT for Prostate Cancer Imaging Using [Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Selective AACS medicinal chemistry letters · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

T BalberBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
J SingerBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
N Berroterán-InfanteBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
M DumanicBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
L FettyBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
J Fazekas-SingerInstitute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8777-3502
C VrakaBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
L NicsBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
M BergmannDepartment of Surgery, Surgical Research Laboratories, Medical University of Vienna, Vienna, Austria.
K PallitschInstitute of Organic Chemistry, University of Vienna, Vienna, Austria.
H SpreitzerDepartment of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
W WadsakBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-4479-8053
M HackerBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
E Jensen-JarolimInstitute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
H ViernsteinDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences, University of Vienna, Vienna, Austria.
M MitterhauserBiomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3173-5272
Medical University of Vienna · ATUniversity of Vienna · ATUniversity of Veterinary Medicine Vienna · ATCenter For Biomarker Research In Medicine · ATKarl Landsteiner University of Health Sciences · ATLudwig Boltzmann Institute Applied Diagnostics · AT

Funding

Austrian Science Fund FWF P 26502
6 · The paper itself

Abstract

Molecular imaging probes such as PET-tracers have the potential to improve the accuracy of tumor characterization by directly visualizing the biochemical situation. Thus, molecular changes can be detected early before morphological manifestation. The A

Indexed as

AnimalsColorectal NeoplasmsFluorine RadioisotopesHeterograftsHT29 CellsHumansMiceMolecular ImagingNeoplasm ProteinsNicotinic AcidsPositron-Emission TomographyRadiopharmaceuticalsReceptor, Adenosine A35-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylateFluorine-18Fluorine RadioisotopesNeoplasm ProteinsNicotinic AcidsRadiopharmaceuticalsReceptor, Adenosine A3

Identifiers

PMID29666562
PMCPMC5830979
OpenAlexW2793470838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.